Cargando…

Risk of COVID-19 after natural infection or vaccination

BACKGROUND: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmoni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rick, Anne-Marie, Laurens, Matthew B., Huang, Ying, Yu, Chenchen, Martin, Thomas C.S., Rodriguez, Carina A., Rostad, Christina A., Maboa, Rebone M., Baden, Lindsey R., El Sahly, Hana M., Grinsztejn, Beatriz, Gray, Glenda E., Gay, Cynthia L., Gilbert, Peter B., Janes, Holly E., Kublin, James G., Huang, Yunda, Leav, Brett, Hirsch, Ian, Struyf, Frank, Dunkle, Lisa M., Neuzil, Kathleen M., Corey, Lawrence, Goepfert, Paul A., Walsh, Stephen R., Follmann, Dean, Kotloff, Karen L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518569/ https://www.ncbi.nlm.nih.gov/pubmed/37738833 http://dx.doi.org/10.1016/j.ebiom.2023.104799

Ejemplares similares

Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials
por: Theodore, Deborah A., et al.
Publicado: (2023)

Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials
por: Lora, Alfredo J. Mena, et al.
Publicado: (2023)

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials
por: Turley, Christine B., et al.
Publicado: (2023)

Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials
por: Follmann, Dean, et al.
Publicado: (2020)

Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial
por: Lin, Dan-Yu, et al.
Publicado: (2022)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
por: Fong, Youyi, et al.
Publicado: (2023)

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
por: Fong, Youyi, et al.
Publicado: (2023)

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
por: Baden, Lindsey R., et al.
Publicado: (2021)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
por: Baden, Lindsey R., et al.
Publicado: (2020)

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
por: Huang, Yunda, et al.
Publicado: (2015)

Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial
por: Fong, Youyi, et al.
Publicado: (2022)

Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region
por: Karuna, Shelly, et al.
Publicado: (2023)

1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves
por: Follmann, Dean, et al.
Publicado: (2023)

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
por: Huang, Ying, et al.
Publicado: (2023)

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
por: Pine, Samuel O., et al.
Publicado: (2011)

A mixed methods investigation of implementation barriers and facilitators to a daily mobile phone sexual risk assessment for young women in Soweto, South Africa
por: Dietrich, Janan J., et al.
Publicado: (2020)

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
por: El Sahly, Hana M., et al.
Publicado: (2021)

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
por: Sadoff, Jerald, et al.
Publicado: (2022)

Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
por: Palli, Rohith, et al.
Publicado: (2020)

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
por: Sadoff, Jerald, et al.
Publicado: (2021)

A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper
por: Laurens, Matthew B, et al.
Publicado: (2019)

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
por: Benkeser, David, et al.
Publicado: (2023)

Wenn Notarzt und Telenotarzt gemeinsam Leben retten: Eine Fallbeschreibung für die Anwendung der prähospitalen Telemedizin bei einer kreislaufinstabilen ventrikulären Tachykardie
por: Follmann, A., et al.
Publicado: (2021)

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
por: Benkeser, David, et al.
Publicado: (2023)

Sizes of atmospheric particulate matters determine the outcomes of their interactions with rainfall processes
por: Maboa, Relotilwe, et al.
Publicado: (2022)

Impact of Exposure to Intimate Partner Violence on CD4+ and CD8+ T Cell Decay in HIV Infected Women: Longitudinal Study
por: Jewkes, Rachel, et al.
Publicado: (2015)

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
por: Gilbert, Peter B., et al.
Publicado: (2021)

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
por: Gilbert, Peter B., et al.
Publicado: (2021)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
por: Buchbinder, Susan P., et al.
Publicado: (2017)

Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine
por: Martin, Troy M., et al.
Publicado: (2023)

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
por: Pajon, Rolando, et al.
Publicado: (2022)

Anthelmintic resistance and prevalence of gastrointestinal nematodes infecting sheep in Limpopo Province, South Africa
por: Mphahlele, Morutse, et al.
Publicado: (2021)

Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models
por: Dimitrov, Dobromir, et al.
Publicado: (2015)

COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective
por: Marcelin, Jasmine R, et al.
Publicado: (2022)

Comparability and reproducibility of biomedical data
por: Huang, Yunda, et al.
Publicado: (2013)

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
por: Follmann, Dean, et al.
Publicado: (2023)

Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa
por: Malahleha, Mookho, et al.
Publicado: (2023)

Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi
por: Meiring, James E, et al.
Publicado: (2019)

A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study
por: Powell, Helen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hn8fgctg427q3fifa41ubeih8p